Shulou(Shulou.com)11/24 Report--

CTOnews.com, November 29, according to CNNC, on November 25, the first boron neutron capture therapy (BNCT) equipment based on intense proton cyclotron in China developed by China Atomic Energy Research Institute of CNNC made a major breakthrough, realized for the first time in the world that 14MeV / 1mA intense proton beam irradiated beryllium target to produce superthermal neutrons, and completed the joint test of neutron source based on 14MeV intense cyclotron.

CNNC said that during the test, the whole equipment worked well and the accelerator neutron source met the design expectations. This marks that the Atomic Energy Institute has broken through all the key technologies of BNCT devices from accelerators, neutron targets to moderators, 100% localization of the main equipment used, and the ability to carry out the design and construction of BNCT commercial machines, which has laid a solid foundation for the next step in the construction of clinical demonstration centers and the development of BNCT industrialization.

BNCT equipment, according to CTOnews.com of CNNC, BNCT (Accelerator Boron Neutron capture Therapy Experimental device) is one of the most cutting-edge cancer targeted therapy technologies in the field of international tumor therapy in recent years, which is often used in head and neck tumors, melanoma and other cancer treatment.

With the support of CNNC, the Atomic Energy Institute successfully completed the BNCT cancer treatment equipment project based on intense current cyclotron. The equipment has the advantages of high flow, low equipment cost, small footprint, high integration and simple operation and maintenance. it is an ideal choice for neutron source of small accelerators in the future and has completely independent intellectual property rights. it was selected as the first batch of nuclear innovation space transformation projects of China Nuclear Corporation. The equipment can be used not only for cancer treatment, but also for the production of radioisotope drugs, for early diagnosis of cancer and cardiovascular and cerebrovascular diseases, to achieve multiple uses of one machine, and is expected to form an industrial scale in high-end medical equipment and reduce treatment costs. so that nuclear science and technology can widely benefit the people.

The project is implemented in cooperation between the Institute of Nuclear Technology of the Atomic Energy Institute and the Institute of reactor Engineering Technology, involving eight research laboratories and four disciplines. The project team cooperated closely to overcome a series of key technical problems, such as intermittent discharge in the central region under the condition of 1mA (milliampere) beam injection acceleration, automatic stable matching of high frequency cavity pressure and phase during beam acceleration, efficient beam transmission of mA magnitude, and beryllium target cooling under 14kW proton beam power.

The epithermal neutron Fluence rate obtained from this test is 1.3E+9 n cm- 2 ·s-1, which is better than the recommended value of 1.0E+9 n cm- 2 ·s-1 set by the International Atomic Energy Agency (IAEA) IAEA-TECDOC-1223 report. It has become the first international BNCT cancer treatment equipment based on 14MeV / 1mA cyclotron to reach the above recommended value. In the next step, the Atomic Energy Institute will speed up the demonstration and industrialization of the plant project, facilitate the landing of the clinical demonstration center as soon as possible, and the United Hospital will jointly carry out clinical demonstration and registration and evidence collection.

Welcome to subscribe "Shulou Technology Information " to get latest news, interesting things and hot topics in the IT industry, and controls the hottest and latest Internet news, technology news and IT industry trends.